In-House vs CRO vs Off-the-Shelf Cell Lines: A Comparison

The first row hides the real difference: in-house is fastest for the second and third line, slowest for the first.

• • You need many lines in a familiar cell type, so the learning curve amortizes.
• • The edit is routine (a straightforward exon deletion) and your delivery protocol is validated.
• • You want to keep IP and sequences inside the lab.
• • You already have cloning and QC capacity that would otherwise idle.

The trap: a lab that builds one line a year pays the full learning curve every time, and usually under-documents it.

• • The cell type is hard to transfect and a failed pilot costs months.
• • The locus is difficult (repeats, extreme GC, essential gene).
• • You need it once, and time-to-data matters more than cash.
• • You need documentation suitable for a partnering or regulatory conversation.

The trap: outsourcing without specifying the QC package. A supplier will deliver what the contract says, and a contract that says "knockout clone" produces a clone whose validation depth you did not define.

• • A validated line already exists for your gene and cell type.
• • The question is a first-pass one where a commercial line is adequate.
• • You need to start immediately and can accept limited documentation.

Three checks before relying on one: identity (STR), the specific edit structure, and whether any functional validation was performed. A catalogue entry is not a validation report.

1. Buy or borrow an off-the-shelf line for a fast first answer.
2. Outsource the line that must be publishable or partnered, with the QC package specified.
3. Build in-house once you have a repeat need and a validated protocol.

This sequence spends money where the evidence matters and saves it where it does not.

Whichever route you choose, specify: genotype with junction sequence, zygosity with method, copy number, protein-level confirmation, matched control, passage at delivery, and the raw data behind each claim. A supplier who cannot provide these is describing a reagent, not a validated model.

Tell us how many lines you need, in which cell types, and what the evidence is for. We will tell you honestly which of the three routes fits — including when the answer is not us.

Contact EDITGENE to request a project consultation or quote.

Cost and timeline ranges vary by locus, cell type, and supplier; the comparison describes structure rather than quotes.

Documentation depth, not price, is the variable most often responsible for irreproducible results across routes.

• • Geraghty RJ, et al. Guidelines for the use of cell lines in biomedical research. British Journal of Cancer. 2014;111:1021–1046.
• • Sentmanat MF, et al. A survey of validation strategies for CRISPR-Cas9 editing. Scientific Reports. 2018;8:888.
• • Ben-David U, et al. Genetic and transcriptional evolution alters cancer cell line drug response. Nature. 2018;560:325–330.